Biopharmaceutical company BioLineRx’s (NASDAQ: BLRX) share price has surged 52% premarket on Friday after the company announced positive results from the interim analysis of its Phase 3 trial of motixafortide.
The Phase 3 trial named GENESIS is assessing the use of motixafortide in stem cell mobilisation (SCM) in multiple myeloma patients.
According to the company, the planned interim analysis of the study’s primary endpoint was conducted independently by the Data Monitoring Committee (DMC) and, based on “statistically significant evidence,” the DMC issued a recommendation that patient enrollment may be ceased immediately.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
It was initially planned that there would be 177 patients conducted into the study, but following the DMC’s recommendation, BioLine said the enrollment is now complete at 122 patients.
“The compelling results of this planned interim analysis are a very significant milestone for our Company, as our SCM program is the Company’s most efficient path to registration for motixafortide,” commented Philip Serlin, CEO of BioLineRx.
The primary endpoint of the study is to “demonstrate that only one dose of motixafortide on top of G-CSF is superior to G-CSF alone in the ability to mobilize > 6×106 CD34+ cells in up to two apheresis sessions,” stated BioLine.
The news has seen BioLine shares rally 52.70% premarket to $2.26 after closing Thursday’s session at $1.48.
PEOPLE WHO READ THIS ALSO VIEWED:
